# Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)

> **NCT02314923** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 513 (actual)

## Conditions studied

- Ebola Virus

## Interventions

- **BIOLOGICAL:** V920 Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02314923
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-05
- **Primary completion:** 2016-06-23
- **Final completion:** 2016-06-23
- **Target enrollment:** 513 (ACTUAL)
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314923, "Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02314923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*